echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The national catalogue of auxiliary drugs is coming out, experts advise the transformation strategy of pharmaceutical enterprises

    The national catalogue of auxiliary drugs is coming out, experts advise the transformation strategy of pharmaceutical enterprises

    • Last Update: 2019-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, some netizens reported to the media that some hospitals have stopped using some auxiliary drugs Driven by policy, how can hospitals, pharmaceutical companies and patients be independent? In December 2018, the national health and Health Commission issued the notice on the management of clinical application of auxiliary drugs (hereinafter referred to as the notice) An important signal conveyed by the red head document is that the national version of the catalogue of auxiliary drugs will be published soon This policy orientation will once again be the focus of monitoring auxiliary drugs to the forefront "From the perspective of the whole country, the introduction of the national auxiliary drug catalogue will effectively control the abuse of auxiliary drugs, and some auxiliary drugs will be stopped." Hu Xin, director of the pharmacy department of Beijing hospital, said that the national policy is based on the interests of patients and will not affect the clinical treatment effect and patients' drug demand Under the heavy pressure, medical institutions have stepped up the pace of focusing on monitoring clinical auxiliary drugs; pharmaceutical companies relying on the production and sales of auxiliary drugs or layoffs, or transformation; patients who use auxiliary drugs will either increase their self payment or face the situation of "unable to buy drugs" According to the notice, local health departments shall submit the list of auxiliary drugs to the national health and Health Commission before December 31, 2018 After the national level defined the deadline, Hainan, Hebei, Anhui, Guangdong and other places have issued documents, requiring local medical institutions to report the directory of auxiliary drugs Taking Hebei Province as an example, the province requires medical institutions to rank the number of drugs by their common name according to the annual use amount, to form a directory of auxiliary drugs, and to submit no less than 20 varieties The health circle learned from the Third Hospital of Hebei Medical University that the hospital has completed the report work within the specified time, and the report varieties are mainly concentrated in traditional Chinese medicine injection and other aspects Data from Hu Xin, the Third Hospital of Hebei Medical University, told the health community that after receiving the notice issued by the national health and Health Commission, Beijing hospital also completed the application for the catalogue of auxiliary drugs according to relevant requirements Hu Xin introduced several principles that Beijing hospital should follow when selecting auxiliary drugs: 1) the amount of drugs used in the hospital ranked in the top 100; 2) those not recommended by the guidelines; 3) those with insufficient clinical evidence; 4) those suitable for various diseases; 5) those not included in the Chinese Pharmacopoeia Generally speaking, those expensive and hard to use "golden oil" are likely to be "kicked out" in the future For the selection of auxiliary drugs, Beijing Hospital of traditional Chinese Medicine Affiliated to Capital Medical University has specially formulated a selection activity Users can select 20 kinds of drugs in a series of list of auxiliary drugs by logging in the selection interface After the issuance of the notice, the evaluation standard of "determining the list of auxiliary drugs according to the order of drug use amount" was regarded as a "one size fits all" approach Some of the opposition believe that this practice may lead to some auxiliary drugs with clinical value being "wronged" In response, Liu Yuehua, deputy researcher of the Health Technology Evaluation Office of the health development research center of the national health and Health Commission, said recently that the original intention of the state's publication of the catalogue of auxiliary drugs is to guide the rational use of drugs, while affirming the role of rational use of auxiliary drugs in alleviating adverse reactions of patients "What the state really cares about is the unreasonable use of super indications, super doses and super courses of treatment, which will not die in a flash." In fact, the impact of the policy has not been maximized As early as before the promulgation of the notice, some provinces and cities have introduced the catalogue of auxiliary drugs, and the use of auxiliary drugs in medical institutions has also been monitored However, the trend of the upcoming national catalogue of auxiliary drugs still has an impact on all parties "For a long time, the abuse of some auxiliary drugs has existed in China." Hu Xin told the health community, for example, the amount of some auxiliary drugs exceeds the amount of tumor targeted drugs Once this happens, the hospital must take measures to limit or stop using As early as 2017, Beijing issued the notice on strengthening the management of key monitoring drugs in medical institutions, which requires medical institutions to list the drugs that are not necessary for treatment and have insufficient evidence of clinical efficacy as "key monitoring drugs", and each medical institution shall establish relevant directories, enter the top 20 key monitoring drugs in medical institutions for three months in a row, and take measures such as limiting or stopping use The monitoring of auxiliary drugs in this document is basically the same as the national version of the notice As the medical insurance fund continues to be tight, many provinces and cities, represented by Sanming City, have already started to use adjuvant drugs It is no surprise that the pharmaceutical reform in 2018 has had a great impact on pharmaceutical companies According to the 2018 semi annual report of Cr 39, the sales and promotion of non clinical first-line drugs such as traditional Chinese medicine injection preparation are facing difficulties due to the pressure of auxiliary drug catalog policy The 2018 semi annual report of Kunming Pharmaceutical Group also shows that the sales volume of the company's leading drug varieties has been reduced by about 26% due to being included in the scope of limiting the use of hospitals above the second level For pharmaceutical companies, the decline in drug sales will undoubtedly make some practitioners worse Influenced by the policies of auxiliary drugs and centralized purchase of drugs, many pharmaceutical companies have taken the step of layoffs At the beginning of 2019, Pfizer announced to close two non patent injection production plants in India, which may cause more than 1700 employees to lose their jobs; on January 8, 2019, Lilly, an American pharmaceutical company, announced to cut 250 jobs; it also announced to lay off old pharmaceutical companies such as AstraZeneca A medical representative in charge of the sales of traditional Chinese medicine injection told the health sector that compared with the previous years, the sales volume had declined significantly, and many medical representatives had to change careers Recently, a medical representative in Jiangxi Province reported to the media that there were more than 80 salespeople in the region, and more than half of them had left in a year Even though there are many sorrows and sorrows, the reform in the field of medicine represented by auxiliary drugs will still be pushed forward in depth Liu Yuehua predicted that in the pharmaceutical reform in 2019, auxiliary drugs should bear the brunt of it and be the first area to be rectified Under the heavy pressure of the policy of focusing on monitoring pharmaceutical enterprises, hospitals have taken multiple measures to monitor auxiliary drugs, and pharmaceutical enterprises have sought the way of transformation ——Hu Xin, the hospital's key monitor, said that in order to control the abuse of auxiliary drugs, Beijing hospital, on the basis of scientific analysis, restricted some departments of auxiliary drugs, restricted the level of prescribing doctors and restricted the types of diseases In addition, some hospitals also realize the above measures through information system In some hospitals, the use of auxiliary drugs in departments is linked to performance appraisal To limit the use of auxiliary drugs, the national health and Health Commission requires medical institutions to formulate technical specifications for the clinical application of auxiliary drugs in their own institutions according to the actual needs of clinical diagnosis and treatment, clearly define the conditions and principles for the clinical application of auxiliary drugs, require doctors to strictly grasp the indications of drug use, strictly follow the instructions of drugs, and do not arbitrarily expand the indications of drug use, change the course of drug use, dosage, etc 。 At the same time, medical institutions should further strengthen the clinical pathway management, scientifically design the clinical pathway, standardize the clinical diagnosis and treatment behavior, focus on monitoring all drugs in the auxiliary drug management directory, strictly implement the prescription review and prescription review system, include all auxiliary drugs in the review and review scope, and give full play to the pharmacists in the auxiliary drug management and clinical drug guidance The function of plane ——Generally speaking, the reason why drugs are listed as auxiliary drugs or monitored is that the therapeutic effect of drugs is not exact, the pharmacological mechanism is not clear and the drugs are not symptomatic Although some drugs were originally therapeutic drugs, they may also become auxiliary drugs due to slow renewal and other reasons Under the condition of the state's restrictions on the use of adjuvant drugs, enterprises still need to "make iron hard by itself" On the way of transformation, Ye Hua, a special contributor of cypress blue, suggested that enterprises should strengthen drug screening and product line combing, strengthen investment in drug research and development and improve drug quality, strengthen clinical efficacy research and strive to make clear drug indications, strengthen the work of entering clinical pathway and disease treatment guidelines and reduce the chance of becoming auxiliary drugs Liu Yuehua suggested that in the future, the key point is to find its own unique value in the clinical pathway Taking the traditional Chinese medicine injection as the representative, part of the auxiliary drugs can find the existing drugs to carry out the combination of drugs, or some injection products can change the drug route to oral dosage form Liu Yuehua said that from the perspective of payment, enterprises or medical institutions can find more payers, such as bundling commercial insurance with a certain treatment drug, which is also a short-term strategy.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.